Microsensor for glucose monitoring hits world-first 10-day milestone
Sava reported clinical evidence its minimally invasive microsensor continuously measured glucose for 10 days, using a filament roughly ten times shorter than traditional CGMs. The London startup raised $32 million, plans a pivotal 2026 study, and targets commercial availability in 2027 pending regulatory approval while developing a modular biomarker platform.
Why it mattersSava's 10-day glucose microsensor and $32 million funding require prioritizing regulatory and manufacturing partnerships.